Vnitr Lek 2024, 70(5):326-334 | DOI: 10.36290/vnl.2024.064

Periprocedural care, bleeding control and rules for the use of antithrombotics in patients with haemostatic disorders in liver disease

MUDr. Jaromír Gumulec
Klinika hematoonkologie FN Ostrava

Prevention and treatment of bleeding or thrombosis in patients with liver cirrhosis is associated with a number of pitfalls, perceived ideas and established stereotypes. A false paradigm persists in the professional community that changes in haemostasis accompanying liver cirrhosis are a priori bleeding. In fact, a new haemostatic balance develops along with liver disease. The problem is that it is fragile and easily disrupted by internal drives or external interventions. The result can be bleeding as well as thrombosis. Inadequate medical interventions conducted in an attempt to correct pathological coagulation abnormalities or thrombocytopenia may contribute to these unfortunate consequences. The present guideline for clinical practice was developed to provide practical guidelines for the interpretation of the results of laboratory tests of haemostasis and platelet count, to summarize current views on haemostasis in liver cirrhosis, rules for the correction of thrombocytopenia and changes in the coagulation system before invasive procedures as well as rules for thromboprophylaxis in hospitalized patients. The main starting point is the recommendation of the European Association for the Study of the Live "Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis".

Keywords: cirrhosis, haemorrhage, haemostasis, liver diseases, thrombocytopenia.

Accepted: August 28, 2024; Published: September 4, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Gumulec J. Periprocedural care, bleeding control and rules for the use of antithrombotics in patients with haemostatic disorders in liver disease. Vnitr Lek. 2024;70(5):326-334. doi: 10.36290/vnl.2024.064.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J Hepatol 2022;76(5):1151-1184. e-pub ahead of print 20220315; doi: 10.1016/j.jhep.2021. 09. 003. Go to original source...
    2. Roberts LN, Lisman T, Stanworth S, et al. Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH. J Thromb Haemost. 2022;20(1):39-47. e-pub ahead of print 20211108; doi: 10.1111/jth.15562. Go to original source... Go to PubMed...
    3. Fejfar T, Vaňásek T, Brůha R, et al. Léčba krvácení v důsledku portální hypertenze při jaterní cirhóze - aktualizace doporučených postupů ČHS ČLS JEP. Gastroent Hepatol. 2017;71(2):105-116. doi: 10.14735/amgh2017105. Go to original source...
    4. Roberts LN, Hernandez-Gea V, Magnusson M, et al. Thromboprophylaxis for venous thromboembolism prevention in hospitalized patients with cirrhosis: Guidance from the SSC of the ISTH. J Thromb Haemos.t 2022;20(10):2237-2245. e-pub ahead of print 20220810; doi: 10.1111/jth.15829 Go to original source... Go to PubMed...
    5. Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010;8(11):2450-2457. doi: 10.1111/j.1538-7836.2010.04044.x Go to original source... Go to PubMed...
    6. Spyropoulos AC, Anderson FA, Jr., FitzGerald G, et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011;140(3):706-714. e-pub ahead of print 20110324; doi: 10.1378/chest.10-1944. Go to original source... Go to PubMed...
    7. Premkumar M, Kulkarni AV, Kajal K, Divyaveer S. Principles, Interpretation, and Evidence-Based Role of Viscoelastic Point-of-Care Coagulation Assays in Cirrhosis and Liver Failure. J Clin Exp Hepatol.2022;12(2):533-543. e-pub ahead of print 20210508; doi: 10.1016/j.jceh.2021. 05. 001. Go to original source...
    8. Kumar M, Ahmad J, Maiwall R, et al. Thromboelastography-Guided Blood Component Use in Patients With Cirrhosis With Nonvariceal Bleeding: A Randomized Controlled Trial. Hepatology. 2020;71(1):235-246. doi: 10.1002/hep.30794. Go to original source... Go to PubMed...
    9. De Pietri L, Bianchini M, Montalti R, et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: A randomized, controlled trial. Hepatology. 2016;63(2):566-573. e-pub ahead of print 20151209; doi: 10.1002/hep.28148. Go to original source... Go to PubMed...
    10. Görlinger K, Pérez-Ferrer A, Dirkmann D, et al. The role of evidence-based algorithms for rotational thromboelastometry-guided bleeding management. Korean J Anesthesiol. 2019;72(4):297-322. e-pub ahead of print 20190517; doi: 10.4097/kja.19169. Go to original source... Go to PubMed...
    11. Fahrendorff M, Oliveri RS, Johansson PI. The use of viscoelastic haemostatic assays in goal-directing treatment with allogeneic blood products - A systematic review and meta-analysis. Scand J Trauma Resusc Emerg Med. 2017;25(1):39. e-pub ahead of print 20170413; doi: 10.1186/s13049-017-0378-9. Go to original source... Go to PubMed...
    12. Poordad F, Terrault NA, Alkhouri N, et al. Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies. Int J Hepatol. 2020;2020:5421632. e-pub ahead of print 2020/02/13; doi: 10.1155/2020/5421632. Go to original source... Go to PubMed...
    13. Terrault N, Chen YC, Izumi N, et al. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia. Gastroenterolog.y 2018;155(3):705-718. e-pub ahead of print 2018/05/21; doi: 10.1053/j.gastro.2018. 05. 025. Go to original source...
    14. von Meijenfeldt FA, van den Boom BP, Adelmeijer J, et al. Prophylactic fresh frozen plasma and platelet transfusion have a prothrombotic effect in patients with liver disease. J Thromb Haemost. 2021;19(3) 664-676. e-pub ahead of print 20201225; doi: 10.1111/jth.15185. Go to original source... Go to PubMed...
    15. Zanetto A, Campello E, Bulato C, et al. Whole blood thrombin generation shows a significant hypocoagulable state in patients with decompensated cirrhosis. Journal of Thrombosis and Haemostasis. 2024;22(2):480-492. doi: 10.1016/j.jtha.2023. 10. 008. Go to original source...
    16. Lebreton A, Mandorfer M. Thrombin generation in cirrhosis: whole blood, whole truth? J Thromb Haemost. 2024;22(2):356-358. doi: 10.1016/j.jtha.2023. 11. 001. Go to original source...
    17. Hashir A, Singh SA, Krishnan G, Subramanian R, et al. Correlation of early ROTEM parameters with conventional coagulation tests in patients with chronic liver disease undergoing liver transplant. Indian J Anaesth. 2019;63(1):21-25. doi: 10.4103/ija.IJA_334_18. Go to original source... Go to PubMed...
    18. Giannini EG, Greco A, Marenco S, et al. Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease. Clin Gastroenterol Hepatol. 2010;8(10):899-902; quiz e109. e-pub ahead of print 2010/07/06; doi: 10.1016/j.cgh.2010. 06. 018. Go to original source...
    19. Afdhal N, McHutchison J, Brown R, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008;48(6):1000-1007. e-pub ahead of print 2008/04/25. doi: 10.1016/j.jhep.2008. 03. 009. Go to original source...
    20. Lang T, von Depka M. Possibilities and limitations of thrombelastometry/-graphy. Hamostaseologie. 2006;26(3 Suppl 1):S20-29. Go to original source...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.